^
Association details:
Biomarker:No biomarker
Cancer:Esophageal Cancer
Drug:oxaliplatin (DNA synthesis inhibitor, DNA cross linking agent)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Esophageal and Esophagogastric Junction Cancers: First-line Therapy...Oxaliplatin is generally preferred over cisplatin due to lower toxicity.